Zhang Yali, Zhang Yu, Deng Hongmei, Zeng Qishu, Zhu Zhu, Zhang Zhaolun, Zhang Chunyu, Li Minghao, Li Jianhong, Li Guang, Feng Jian
Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China.
Key Laboratory of Medical Electrophysiology of the Ministry of Education, Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, China.
Phytomedicine. 2025 Sep;145:157006. doi: 10.1016/j.phymed.2025.157006. Epub 2025 Jun 20.
Septic cardiomyopathy (SCM) is associated with sepsis and is often accompanied by progressive arrhythmia. Naringenin (Nar) is a natural dihydroflavonoid compound that plays a protective role in various cardiovascular diseases. Calcium/calmodulin-dependent kinase II (CaMKII) is a key therapeutic target in cardiac arrhythmias.
This study investigated the effect of naringenin on arrhythmia and cardiac electrophysiology in SCM and explored the mechanism involved.
Lipopolysaccharide was used to establish SCM in a mouse model and in an H9c2 cell line. The protective role of naringenin in SCM was investigated by pretreatment with naringenin, amiodarone, and a CaMKII inhibitor (KN-93). Cardiac function, susceptibility to arrhythmia, and electrophysiological changes were assessed in the mice using echocardiography, electrocardiography, and optical mapping techniques. Network pharmacology approaches, molecular docking, and molecular dynamics simulations were used to screen for pivotal targets. The mechanism(s) underlying the protective impact of naringenin on SCM were examined in vivo, ex vivo, and in vitro.
Naringenin protected against SCM by exerting anti-inflammatory effects, alleviating myocardial injury, improving cardiac dysfunction, reducing the susceptibility to arrhythmia, and stabilizing electrophysiology. Network pharmacology, molecular docking, and molecular dynamics simulations indicated that the key target protein of naringenin may be Bcl-2. Further studies confirmed that naringenin attenuated apoptosis, improved mitochondrial dysfunction, and downregulated the CaMKⅡ/Drp1/Bcl-2 pathway in SCM.
Naringenin attenuates the phosphorylation of Drp1 by inhibiting phosphorylation of CaMKⅡ, thereby ameliorating mitochondrial dysfunction, suppressing apoptosis, modulating myocardial electrophysiology, and ultimately reducing susceptibility to arrhythmia while improving cardiac function in SCM.
脓毒症性心肌病(SCM)与脓毒症相关,常伴有进行性心律失常。柚皮素(Nar)是一种天然二氢黄酮类化合物,在多种心血管疾病中发挥保护作用。钙/钙调蛋白依赖性激酶II(CaMKII)是心律失常的关键治疗靶点。
本研究探讨柚皮素对SCM心律失常和心脏电生理学的影响,并探究其相关机制。
采用脂多糖在小鼠模型和H9c2细胞系中建立SCM。通过柚皮素、胺碘酮和CaMKII抑制剂(KN-93)预处理研究柚皮素在SCM中的保护作用。使用超声心动图、心电图和光学映射技术评估小鼠的心脏功能、心律失常易感性和电生理变化。采用网络药理学方法、分子对接和分子动力学模拟筛选关键靶点。在体内、离体和体外研究柚皮素对SCM保护作用的潜在机制。
柚皮素通过发挥抗炎作用、减轻心肌损伤、改善心脏功能障碍、降低心律失常易感性和稳定电生理学来保护SCM。网络药理学、分子对接和分子动力学模拟表明,柚皮素的关键靶蛋白可能是Bcl-2。进一步研究证实,柚皮素可减轻SCM中的细胞凋亡、改善线粒体功能障碍并下调CaMKⅡ/Drp1/Bcl-2通路。
柚皮素通过抑制CaMKⅡ的磷酸化来减弱Drp1的磷酸化,从而改善线粒体功能障碍、抑制细胞凋亡、调节心肌电生理学,并最终降低SCM中心律失常的易感性,同时改善心脏功能。